Polyrizon Ltd.(PLRZ)Earnings, Financials & Key Ratios

PLRZ•NASDAQ

$15.21

Price updated Jul 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryDrug Delivery Technology Platforms

AboutPolyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.Show more

Revenue$0
EBITDA-$6M-398.9%
Net Income-$3M-115.9%
EPS (Diluted)-2.07+98.5%
ROE-25.38%+56.1%

PLRZ Price & Volume

Polyrizon Ltd. (PLRZ) stock price & volume — 10-year historical chart

Loading chart...

Pre-Revenue Development Status Masks Liquidity Shortfall

Investment Thesis • Updated 2025Q4

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Imminent liquidity depletion risk

Key Thesis Takeaways

Polyrizon remains a speculative, pre-revenue biotechnology entity currently facing an acute liquidity crisis as its cash reserves dwindled from $15.8 million in 2025Q2 to $1.3 million by 2025Q4.
The company's aggressive R&D and SG&A spending, which totaled $3.7 million in 2025Q4, appears disconnected from its lack of commercial product sales, creating significant uncertainty regarding its long-term operational viability.
Investors should monitor the firm's ability to secure additional capital, as the current burn rate suggests an imminent risk of a going concern event.

Verdict Logic

the company's rapid cash depletion, evidenced by a decline from $15.8 million to $1.3 million in just two quarters, presents an unsustainable risk profile for institutional investors.

PLRZ Growth Metrics

Polyrizon Ltd. (PLRZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-115.75%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM97.36%

Return on Capital

10 Years-2495.14%

5 Years-3006.43%

3 Years-403.44%

Last Year-47.56%

Latest PLRZ News

Recent stock market news and headlines for Polyrizon Ltd. (PLRZ)

GlobeNewsWire·4 days ago

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced successful results from its biocompatibility evaluation program for its proprietary NASARIXTM Allergy Blocker nasal spray, with all required biological safety tests meeting their predetermined acceptance criteria.

Globe News Wire·4 days ago

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced successful results from its biocompatibility evaluation program for its proprietary NASARIXTM Allergy Blocker nasal spray, with all required biological safety tests meeting their predetermined acceptance criteria.

GlobeNewsWire·Jun 29, 2026

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, announced it has received central IRB approval to begin its first human clinical trial for NASARIX™, the Company's innovative nasal spray designed to block airborne allergens.

GlobeNewsWire·Jun 17, 2026

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of U.S. patent application No. US 2024/0358741 A1, titled “Mucoadhesive Polymers for Nasal Drug Delivery”.

Peers Comparison

Key metrics vs top competitors for Polyrizon Ltd. (PLRZ)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
PLRZPolyrizon Ltd.Current	$15.21	$17.04M	-7.35	—	—	-25.38%	—
SIGASIGA Technologies, Inc.	$3.75	$268.97M	11.36	-31.8%	21.61%	10.62%	—
AGENAgenus Inc.	$3.41	$142M	-1002.94	10.37%	52.16%	—	—
NVAXNovavax, Inc.	$9.35	$1.54B	3.68	64.69%	-14.73%	—	—
NRXPNRx Pharmaceuticals, Inc.	$3.95	$68.19M	-2.94	—	-1070.26%	—	—
PRPHProPhase Labs, Inc.	$0.07	$342.01K	-0.04	-35.82%	-709.4%	-453.74%	—

Compare PLRZ vs Peers

Polyrizon Ltd. (PLRZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SIGA

Most directly comparable listed peer for PLRZ.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare PLRZ against a more recognizable public peer.

Peer Set

Compare Top 5

vs SIGA, AGEN, NVAX, NRXP

Get notified when PLRZ posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

PLRZ Frequently Asked Questions

Polyrizon Ltd. (PLRZ) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Is PLRZ profitable?

Polyrizon Ltd. (PLRZ) reported a net loss of $3.3M for fiscal year 2025.

Dividend & Returns

What is PLRZ's return on equity?

Polyrizon Ltd. (PLRZ) has a return on equity (ROE) of -25.4%. Negative ROE indicates the company is unprofitable.

What is Polyrizon Ltd.'s free cash flow?

Polyrizon Ltd. (PLRZ) had negative free cash flow of $4.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in PLRZ back in 2020?

Total return calculator · dividends reinvested · 6+ years of data

See returns →

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

PLRZPolyrizon Ltd.Current

$15.21

$17.04M

-7.35

—

-25.38%

—

SIGASIGA Technologies, Inc.

$3.75

$268.97M

11.36

-31.8%

21.61%

10.62%

—

AGENAgenus Inc.

$3.41

$142M

-1002.94

10.37%

52.16%

—

NVAXNovavax, Inc.

$9.35

$1.54B

3.68

64.69%

-14.73%

—

NRXPNRx Pharmaceuticals, Inc.

$3.95

$68.19M

-2.94

—

-1070.26%

—

PRPHProPhase Labs, Inc.

$0.07

$342.01K

-0.04

-35.82%

-709.4%

-453.74%

—